Drug | Tablet
Voglibose 0.2 mg
Type 2 diabetes mellitus; used to reduce post-meal (postprandial) blood glucose as an add-on to diet/exercise and other antidiabetic medicines
Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion in the small intestine. This slows glucose absorption after meals, thereby reducing postprandial blood sugar spikes.
Oral tablet. Usually taken immediately before the start of each main meal (or with the first bite of food) as prescribed. If you skip a meal, skip the dose. Follow diet and exercise advice and monitor blood glucose regularly.
Common side effects of Volibo 0.2 Tablet may include:
Use with caution in liver disease; periodic liver function monitoring may be advised. Not recommended in inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, chronic intestinal diseases with digestion/absorption disorders, or severe renal impairment unless advised by a doctor. Risk of hypoglycaemia increases when combined with insulin or sulfonylureas—carry glucose (dextrose) for treatment of low sugar (table sugar may act slowly). Seek medical help for severe abdominal symptoms or signs of liver injury (jaundice, dark urine).
